Cover Image
Market Research Report

Bullous Pemphigoid - Pipeline Review, H1 2017

Published by Global Markets Direct Product code 410984
Published Content info 51 Pages
Immediate Delivery Available
Price
Back to Top
Bullous Pemphigoid - Pipeline Review, H1 2017
Published: June 13, 2017 Content info: 51 Pages
Description

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bullous Pemphigoid - Pipeline Review, H1 2017, provides an overview of the Bullous Pemphigoid (Dermatology) pipeline landscape.

Bullous pemphigoid is a chronic, inflammatory, subepidermal, blistering disease. If untreated, it can persist for months or years, with periods of spontaneous remissions and exacerbations. The disease can be fatal, particularly in patients who are debilitated.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bullous Pemphigoid - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Bullous Pemphigoid (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bullous Pemphigoid (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Bullous Pemphigoid and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2 and 1 respectively.

Bullous Pemphigoid (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Bullous Pemphigoid (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Bullous Pemphigoid (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Bullous Pemphigoid (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Bullous Pemphigoid (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Bullous Pemphigoid (Dermatology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Bullous Pemphigoid (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Bullous Pemphigoid (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC9420IDB

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Bullous Pemphigoid - Overview
  • Bullous Pemphigoid - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
  • Bullous Pemphigoid - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Bullous Pemphigoid - Companies Involved in Therapeutics Development
  • Akari Therapeutics Plc
  • Eli Lilly and Company
  • iCo Therapeutics Inc.
  • Immungenetics AG
  • TxCell SA
  • Bullous Pemphigoid - Drug Profiles
  • bertilimumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Coversin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • dimethyl fumarate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ENTX-BP - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ixekizumab - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • TNT-009 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Bullous Pemphigoid - Dormant Projects
  • Bullous Pemphigoid - Product Development Milestones
  • Featured News & Press Releases
  • Feb 28, 2017: Immune Pharmaceuticals Reports Encouraging Preliminary Data with Bertilimumab in an Open Label Phase 2 Study in the Rare Dermatological Auto-Immune Disease, Bullous Pemphigoid
  • Jun 14, 2016: Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States
  • Nov 09, 2015: Immune Pharmaceuticals Announces FDA Acceptance of Investigational New Drug (IND) Application in the U.S. for Bertilimumab for the Treatment of Bullous Pemphigoid
  • Oct 07, 2015: Immune Pharmaceuticals Submits Investigational New Drug Application in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid
  • Jul 13, 2015: Immune Pharmaceuticals to present bertilimumab at The International Eosinophil Society workshop on Personalized Medicine
  • Jun 25, 2015: Immune Pharmaceuticals Initiates Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis And Bullous Pemphigoid
  • Mar 31, 2015: Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab
  • Feb 05, 2015: Immune Pharmaceuticals To Present At The BIO CEO & Investor Conference
  • Dec 09, 2014: CEO Dr. Daniel Teper of Immune Pharmaceuticals to Be Interviewed Live on Clear Channel - iHeart Business Talk Radio - December 9, 2014
  • Jul 30, 2014: Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Bullous Pemphigoid, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Products under Development by Companies, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Bullous Pemphigoid - Pipeline by Akari Therapeutics Plc, H1 2017
  • Bullous Pemphigoid - Pipeline by Eli Lilly and Company, H1 2017
  • Bullous Pemphigoid - Pipeline by iCo Therapeutics Inc., H1 2017
  • Bullous Pemphigoid - Pipeline by Immungenetics AG, H1 2017
  • Bullous Pemphigoid - Pipeline by TxCell SA, H1 2017
  • Bullous Pemphigoid - Dormant Projects, H1 2017

List of Figures

  • Number of Products under Development for Bullous Pemphigoid, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Targets, H1 2017
  • Number of Products by Stage and Targets, H1 2017
  • Number of Products by Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top